Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference.

Hamaguchi’s score biomarkers diagnostics hepatorenal index liver steatosis

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
04 Apr 2021
Historique:
received: 03 03 2021
revised: 31 03 2021
accepted: 01 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

In view of the limited reliability of biopsies in the assessment of liver fat, a non-invasive, trustworthy, and more accessible method estimating a degree of steatosis is urgently needed. While the controlled attenuation parameter (CAP) is used to quantify hepatic fat, its availability in routine practice is limited. Therefore, the aim of this study was to compare the diagnostic accuracy of biomarker- and ultrasound-based techniques for the diagnosis and grading of hepatic steatosis. This was a prospective study of 167 adults with and without non-alcoholic fatty liver disease. As measured against CAP, we assessed Hamaguchi's score and the hepatorenal index (HRI), and the following biochemical measures: the fatty liver index, hepatic steatosis index, and lipid accumulation product scores during a single out-patient visit. Area under the receiver operating curve (AUROC) analyses were used to evaluate the diagnostic accuracy of each test and to calculate optimal thresholds for the ultrasound techniques. All non-invasive methods displayed high accuracy in detecting steatosis (mean AUC value ≥ 0.90), with Hamaguchi's score and the HRI being the most precise. These two tests also had the highest sensitivity and specificity (82.2% and 100%; 86.9% and 94.8%, respectively). We propose new thresholds for Hamaguchi's score and HRI for hepatic steatosis grading, indicated by optimal sensitivity and specificity. Ultrasound-based techniques are the most accurate for assessing liver steatosis compared to other non-invasive tests. Given the accessibility of ultrasonography, this finding is of practical importance for the assessment of liver steatosis in clinical settings.

Sections du résumé

BACKGROUND & AIMS OBJECTIVE
In view of the limited reliability of biopsies in the assessment of liver fat, a non-invasive, trustworthy, and more accessible method estimating a degree of steatosis is urgently needed. While the controlled attenuation parameter (CAP) is used to quantify hepatic fat, its availability in routine practice is limited. Therefore, the aim of this study was to compare the diagnostic accuracy of biomarker- and ultrasound-based techniques for the diagnosis and grading of hepatic steatosis.
METHODS METHODS
This was a prospective study of 167 adults with and without non-alcoholic fatty liver disease. As measured against CAP, we assessed Hamaguchi's score and the hepatorenal index (HRI), and the following biochemical measures: the fatty liver index, hepatic steatosis index, and lipid accumulation product scores during a single out-patient visit. Area under the receiver operating curve (AUROC) analyses were used to evaluate the diagnostic accuracy of each test and to calculate optimal thresholds for the ultrasound techniques.
RESULTS RESULTS
All non-invasive methods displayed high accuracy in detecting steatosis (mean AUC value ≥ 0.90), with Hamaguchi's score and the HRI being the most precise. These two tests also had the highest sensitivity and specificity (82.2% and 100%; 86.9% and 94.8%, respectively). We propose new thresholds for Hamaguchi's score and HRI for hepatic steatosis grading, indicated by optimal sensitivity and specificity.
CONCLUSIONS CONCLUSIONS
Ultrasound-based techniques are the most accurate for assessing liver steatosis compared to other non-invasive tests. Given the accessibility of ultrasonography, this finding is of practical importance for the assessment of liver steatosis in clinical settings.

Identifiants

pubmed: 33916626
pii: jcm10071507
doi: 10.3390/jcm10071507
pmc: PMC8038574
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK123704
Pays : United States

Références

Clin Liver Dis. 2018 Feb;22(1):73-92
pubmed: 29128062
AJR Am J Roentgenol. 2009 Apr;192(4):909-14
pubmed: 19304694
JGH Open. 2019 Dec 17;4(3):497-502
pubmed: 32514460
J Clin Ultrasound. 2013 Jan;41(1):18-25
pubmed: 22997020
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Gastroenterol Hepatol. 2018 Jan;33(1):270-276
pubmed: 28464337
PLoS One. 2014 Mar 17;9(3):e91987
pubmed: 24637477
Hepatology. 2018 Apr;67(4):1348-1359
pubmed: 29108123
World J Gastroenterol. 2016 Mar 14;22(10):3023-30
pubmed: 26973398
Endocr Connect. 2020 Feb;9(2):154-162
pubmed: 31910158
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
World J Hepatol. 2017 Jun 8;9(16):715-732
pubmed: 28652891
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
Liver Int. 2014 Jul;34(6):e111-7
pubmed: 24034415
World J Gastroenterol. 2019 Oct 28;25(40):6053-6062
pubmed: 31686762
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1201-4
pubmed: 23353640
J Clin Ultrasound. 2016 Nov 12;44(9):580-586
pubmed: 27447717
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
BMC Gastroenterol. 2010 Aug 25;10:98
pubmed: 20738844
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Hepatol. 2017 May;66(5):1022-1030
pubmed: 28039099
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22
pubmed: 25267215
Clin Gastroenterol Hepatol. 2020 Nov 9;:
pubmed: 33249025
AJR Am J Roentgenol. 2012 Nov;199(5):997-1002
pubmed: 23096171
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
BMC Gastroenterol. 2019 Apr 8;19(1):51
pubmed: 30961539
Am J Gastroenterol. 2007 Dec;102(12):2708-15
pubmed: 17894848
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Cells. 2020 Apr 17;9(4):
pubmed: 32316690
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1842-1850.e6
pubmed: 31843596
World J Hepatol. 2020 Apr 27;12(4):149-159
pubmed: 32685107
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575

Auteurs

Katarzyna Kozłowska-Petriczko (K)

Translational Medicine Group, Pomeranian Medical University, 70-204 Szczecin, Poland.
Department of Gastroenterology and Internal Medicine, SPWSZ Hospital, 71-455 Szczecin, Poland.

Ewa Wunsch (E)

Translational Medicine Group, Pomeranian Medical University, 70-204 Szczecin, Poland.

Jan Petriczko (J)

Department of Plastic, Endocrine and General Surgery, Pomeranian Medical University, 70-204 Szczecin, Poland.

Wing-Kin Syn (WK)

Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC 29425, USA.

Piotr Milkiewicz (P)

Translational Medicine Group, Pomeranian Medical University, 70-204 Szczecin, Poland.
Liver and Internal Medicine Unit, Medical University of Warsaw, 02-097 Warsaw, Poland.

Classifications MeSH